Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis

Biomarkers

Volumn 13, Issue 1, 2008, Pages 59-78

  Knudsen, Lene S ^a   Christensen, Ib J ^a,b   Lottenburger, Tine ^c   Svendsen, Mads N ^a   Nielsen, Hans J ^a   Nielsen, Lone ^a   Hørslev Petersen, Kim ^c   Jensen, Jens E B ^a   Kollerup, Gina ^a   Johansen, Julia S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biological variation; Biomarker; IL 6; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 6;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYCLING; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE THAWING; HUMAN; MALE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; CIRCADIAN RHYTHM; EXERCISE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; REFERENCE VALUES;

EID: 38049187988     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500701615017     Document Type: Article

References (71)

1. Akira, S., Taga, T. and Kishimoto, T. (1993) Interleukin-6 in biology and medicine. Advances in Immunology, 54, pp. 1-78.
2. Arnett, FC, Edworthy, SM, Bloch, DA, McShane, DJ, Fries, JF, Cooper, NS, Healey, LA, Kaplan, SR, Liang, MH and Luthra, HS. (1987) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism, 31, pp. 315-324.
3. Arvidson, NG, Gudbjornsson, B., Elfman, L., Ryden, AC, Totterman, TH and Hallgren, R. (1994) Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Annals of the Rheumatic Diseases, 53, pp. 521-524.
4. Atkinson, A. (2001) Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics, 69, pp. 89-95.
5. Atreya, R. and Neurath, M. (2005) Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clinical Review Allergy and Immunology, 28, pp. 187-195.
6. Barrera, P., Joosten, LA, Broeder, AA den, van de Putte, LB, van Riel, PL and Berg, WB. van den (2001) Effects of treatment with a fully human anti-tumor necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-alpha in patients with rheumatoid arthritis. Annals of Rheumatic Disease, 60, pp. 660-669.
7. Bauer, J., Hohagen, F., Ebert, T., Timmer, J., Ganter, U., Krieger, S., Lis, S., Postler, E., Voderholzer, U. and Berger, M. (1994) Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clinical Investigation, 72, p. 315.
8. Boe, A., Baiocchi, M., Carbonatto, M., Papoian, R. and Serlupi-Crescenzi, O. (1999) Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine, 11, pp. 1057-1064.
9. Caruso, C., Lio, D., Cavallone, L. and Franceschi, C. (2004) Aging, longevity, inflammation, and cancer. Annals of the New York Academy of Science, 1028, pp. 1-13.
10. Cava, F., Gonzalez, C., Pascuel, M., Navajo, J. and Gonzalez-Buitrago, J. (2000) Biological variation of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in serum of healthy individuals. Cytokine, 12, pp. 1423-1425.
11. Choy, EH, Isenberg, DA, Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., Yoshizaki, K., Nishimoto, N., Kishimoto, T. and Panayi, GS. (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatism, 46, pp. 3143-3150.
12. Choy, EH and Panayi, G. (2001) Cytokine pathway and joint inflammation in rheumatoid arthritis. New England Journal of Medicine, 344, pp. 907-916.
13. Crilly, A., McInness, IB, McDonald, AG, Watson, J., Capell, HA and Madhok, R. (1995) Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. Journal of Rheumatology, 22, pp. 224-226.
14. Crofford, LJ, Kalogeras, KT, Mastorakos, G., Magiakou, MA, Wells, J., Kanik, KS, Gold, PW, Chrousos, GP and Wilder, RL. (1997) Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. Journal of Clinical Endocrinology and Metabolism, 82, pp. 1279-1283.
15. Cutolo, N., Otsa, K., Aakre, O. and Sulli, A. (2005) Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Annals of the New York Academy of Science, 1051, pp. 372-381.
16. Dasgupta, B., Corkill, M., Kirkham, B., Gibson, T. and Panayi, G. (1992) Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. Journal of Rheumatology, 19, pp. 22-25.
17. De Jongh, R., Vranken, J., Vundelinckx, G., Bosmans, E., Maes, M. and Heylen, R. (1997) The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. Cytokine, 9, pp. 696-701.
18. Drynda, S., Kuhne, C. and Kekow, J. (2002) Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Annals of Rheumatic Diseases, 61, pp. 254-256.
19. Febbraio, MA and Pedersen, BK. (2002) Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. Journal of the Federation of American Societies for Experimental Biology, 16, pp. 1335-1347.
20. Franchimont, N., Wertz, S. and Malaise, M. (2005) Interleukin-6: An osteotropic factor influencing bone formation?. Bone, 37, pp. 601-606.
21. Fried, S., Bunkin, D. and Greenberg, A. (1998) Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism, 83, pp. 847-850.
22. Georganas, C., Liu, H., Perlman, H., Hoffmann, A., Thimmapaya, B. and Pope, RM. (2000) Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: The dominant role for NF-kappa B but not C/EBP beta or c-Jun. Journal of Immunology, 165, pp. 7199-7206.
23. Guerne, PA, Zuraw, BL, Vaughan, JH, Carson, DA and Lotz, M. (1989) Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. Journal of Clinical Investigation, 83, pp. 585-592.
24. Haddy, N., Sass, C., Maumus, S., Marie, B., Droesch, S., Siest, G., Lambert, D. and Visvikis, S. (2005) Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. European Journal of Human Genetics, 13, pp. 109-117.
25. Hager, K., Machein, U., Krieger, S., Platt, D., Seefried, G. and Bauer, J. (1994) Interleukin-6 and selected plasma protein in healthy persons of different ages. Neurobiology of Aging, 15, pp. 771-772.
26. Harris, T., Ferrucci, L., Tracy, R., Corti, C., Wacholder, S., Ettinger, W., Heimovitz, H., Cohen, H. and Wallace, R. (1999) Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. American Journal of Medicine, 106, pp. 506-512.
27. Ho, GYF, Xue, X., Burk, RD, Kaplan, RC, Cornell, E. and Cushman, M. (2005) Variability of serum levels of tumor necrosis factor alpha, interleukin-6, and soluble interleukin-6 receptor over 2 years in young women. Cytokine, 30, pp. 1-6.
28. Hong, S., Mills, P., Loredo, J., Adler, K. and Dimsdale, J. (2004) The association between interleukin-6, sleep, and demographic characteristics. Brain. Behavior and Immunity, 19, pp. 165-172.
29. Houssiau, F., Devogelaer, JP, Van, DJ, de Deuxchaisnes, CN and Van, SJ. (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis and Rheumatism, 31, pp. 784-788.
30. Ishihara, K. and Hirano, T. (2002) IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Review, 13, pp. 357-368.
31. Jensen, JEB, Kollerup, G., Sørensen, HA, Nielsen, SP and Sørensen, OH. (1997) A single measurement of biochemical markers of bone turnover has limited utility in the individual person. Scandinavian Journal of Clinical Laboratory Investigation, 57, pp. 351-360.
32. Kamimura, D., Ishihara, K. and Hirano, T. (2003) IL-6 signal transduction and its physiological roles: The signal orchestration model. Review of Physiology. Biochemistry and Pharmacology, 149, pp. 1-38.
33. Kenis, G., Teunnissen, C., De Jongh, R., Bosmans, E., Steinbusch, H. and Maes, M. (2002) Stability of interleukin-6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine, 19, pp. 228-235.
34. Kirkwood, TBL. (1979) Geometric means and measures of dispersion. Biometrics, 35, pp. 908-909.
35. Knudsen, LS, Østergaard, M., Baslund, B., Narvestad, E., Petersen, J., Nielsen, HJ, Ejbjerg, BJ, Szkudlarek, M. and Johansen, JS. (2006) Plasma IL-6, plasma VEGF, and serum YKL-40: Relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scandinavian Journal of Rheumatology, 35, pp. 489-495.
36. Kotake, S., Sato, K., Kim, KJ, Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T. and Kashiwazaki, S. (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. Journal of Bone and Mineral Research, 11, pp. 88-95.
37. Madhok, R., Crilly, A., Murphy, E., Smith, J., Watson, J. and Capell, HA. (1993) Gold therapy lowers serum interleukin 6 levels in rheumatoid arthritis. Journal of Rheumatology, 20, pp. 630-633.
38. Maggio, M., Guralnik, JM, Longo, DL and Ferrucci, L. (2006) Interleukin-6 in aging and chronic disease: A magnificent pathway. Journal of Gerontology, 61, pp. 575-584.
39. Maini, RN, Taylor, PC, Szechinski, J., Pavelka, K., Broll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., Thomson, D. and Kishimoto, T. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis and Rheumatism, 54, pp. 2817-2829.
40. Manicourt, DH, Triki, R., Fukuda, K., Devogelaer, JP, de, DC Nagant and Thonar, EJ. (1993) Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis and Rheumatism, 36, pp. 490-499.
41. McInnes, IB and Liew, FY. (2005) Cytokine networks - towards new therapies for rheumatoid arthritis. Nature Clinical Practice Rheumatology, 1, pp. 31-39.
42. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D., Miles, J., Yudkin, J., Klein, S. and Coppack, S. (1997) Subcutaneous adipose tissue release interleukin-6, but not tumor necrosis factor alpha in vivo. Journal of Clinical Endocrinology and Metabolism, 82, pp. 4196-4200.
43. Nagaraju, K., Raben, N., Merritt, G., Loeffler, L., Kirk, K. and Plotz, P. (1998) A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clinical Experimental Immunology, 113, pp. 407-414.
44. Nishimoto, N., Kishimoto, T. and Yoshizaki, K. (2000) Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Annals of Rheumatic Diseases, 59, pp. i21-i27.
45. Nishimoto, N., Yoshizaki, K., Maeda, K., Kuritani, T., Deguchi, H., Sato, B., Imai, N., Suemura, M., Kakehi, T., Takagi, N. and Kishimoto, T. (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. Journal of Rheumatology, 30, pp. 1426-1435.
46. Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J. and Kishimoto, T. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 50, pp. 1761-1769.
47. Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M. and Kishimoto, T. (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proceedings in Natural Academy of Science USA, 95, pp. 8222-8226.
48. Pantsulaia, I., Trofimov, S., Kobyliansky, E. and Livshits, G. (2002) Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population. Cytokine, 19, pp. 138-146.
49. Papanicolaou, DA, Wilder, RL, Manolagas, SC and Chrousos, GP. (1998) The pathophysiologic role of interleukin-6 in human disease. Annals of Internal Medicine, 128, pp. 127-137.
50. Pedersen, BK and Hoffman-Goetz, L. (2000) Exercise and the immune system: Regulation, integration, and adaptation. Physiological Reviews, 80, pp. 1055-1081.
51. Penkowa, M., Keller, C., Keller, P., Jauffred, S. and Pedersen, B. (2003) Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. Journal of the Federation of American Societies for Experimental Biology (online)
52. Popa, C., Netea, MG, Barrera, P., Radstake, TR, van Riel, PL, Kullberg, BJ and van der Meer, JW. (2005) Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy. Cytokine, 30, pp. 72-77.
53. Popa, C., Netea, MG, Radstake, TR, van Riel, PL, Barrera, P. and van der Meer, JW. (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Annals of Rheumatic Diseases, 64, pp. 1195-1198.
54. Riches, P., Gooding, R., Millar, B. and Rowbottom, A. (1992) Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. Journal of Immunological Methods, 153, pp. 125-131.
55. Sack, U., Kinne, RW, Marx, T., Heppt, P., Bender, S. and Emmrich, F. (1993) Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatology International, 13, pp. 45-51.
56. Sasai, M., Saeki, Y., Ohshima, S., Nishioka, K., Mima, T., Tanaka, T., Katada, Y., Yoshizaki, K., Suemura, M. and Kishimoto, T. (1999) Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis and Rheumatism, 42, pp. 1635-1643.
57. Scheller, J., Ohnesorge, N. and Rose-John, S. (2006) Interleukin-6 trans-signalling in chronic inflammation and cancer. Scandinavian Journal of Immunology, 63, pp. 321-329.
58. Smolen, JS, Redlich, K., Zwerina, J., Aletaha, D., Steiner, G. and Schett, G. (2005) Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clinical Review in Allergy and Immunology, 28, pp. 239-248.
59. Sothern, RB, Roitman-Johnson, B., Kanabrocki, EL, Yager, JG, Fuerstenberg, RK, Weatherbee, JA, Young, MR, Nemchausky, BM and Scheving, LE. (1995) Circadian characteristics of interleukin-6 in blood and urine of clinically healthy men. In Vivo, 9, pp. 331-339.
60. Sothern, RB, Roitman-Johnson, B., Kanabrocki, EL, Yager, JG, Roodell, MM, Weatherbee, JA, Young, MR, Nenchausky, BM and Scheving, LE. (1995) Circadian characteristics of circulating interleukin-6 in men. Journal of Allergy and Clinical Immunology, 95, pp. 1029-1035.
61. Spranger, J., Kroke, A., Mohlig, M., Hoffmann, K., Bergman, M., Ristow, M., Boeing, H. and Pfeiffer, A. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the Prospective Population-Based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes, 52, pp. 812-817.
62. Starkie, R., Arkinstall, M., Koukoulas, I., Hawley, J. and Febbraio, M. (2001) Carbohydrate ingestion attenuates the increase in plasma interleukin-6 mRNA during exercise in humans. Journal of Physiology, 533, pp. 585-591.
63. Straub, RH, Harle, P., Yamana, S., Matsuda, T., Takasugi, K., Kishimoto, T. and Nishimoto, N. (2006) Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 54, pp. 1778-1785.
64. Swaak, AJ, van, RA, Nieuwenhuis, E. and Aarden, LA. (1988) Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scandinavian Journal of Rheumatology, 17, pp. 469-474.
65. Thavasu, P., Longhurst, S., Joel, S., Slevin, M. and Balkwill, F. (1992) Measuring cytokine levels in blood. Journal of Immunological Methods, 153, pp. 155-124.
66. Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, DM, Martin, TJ, Hirota, H., Taga, T., Kishimoto, T. and Suda, T. (1995) Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. Journal of Experimental Medicine, 182, pp. 1461-1468.
67. Vgontzas, AN, Zoumakis, E., Bixler, EO, Lin, HM, Follett, H., Kales, A. and Chrousos, GP. (2004) Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. Journal of Clinical Endocrinology and Metabolism, 89, pp. 2119-2126.
68. Vgontzas, A., Bixler, E., Lin, H., Prolo, P., Trakada, G. and Chrousos, G. (2005) IL-6 and its circardian secretion in humans. NeuroImmunoModulation, 12, pp. 131-140.
69. Wei, J., Xu, H., Davis, J. and Hemmings, G. (1992) Increase of plasma IL-6 concentration with age in healthy subjects. Life Science, 51, pp. 1953-1956.
70. Wendling, D., Racadot, E. and Wijdenes, J. (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. Journal of Rheumatology, 20, pp. 259-262.
71. Wong, PK, Campbell, IK, Egan, PJ, Ernst, M. and Wicks, IP. (2003) The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis and Rheumatism, 48, pp. 1177-1189.